There is a newer version of this record available.

Report Open Access

Statistical review of A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 by B. Cao et al

Gates, Simon; Emsley, Richard; Dahly, Darren

The following review has been prepared in collaboration with members of the MRC-NIHR Trials Methodology Research Partnership. The reviewers named above, and other, unnamed discussants of the paper, are all qualified statisticians with experience in clinical  trials. Our objective is to provide a rapid review of publications, preprints and protocols from clinical trials of COVID-19 treatments,  independent of journal specific review processes. We aim to provide timely, constructive, focused, clear advice aimed at improving both the research outputs under review, as well as future studies. Given our collective expertise (clinical trial statistics) our reviews  focus on the designs of the trials and other statistical content (methods, presentation and accuracy of results, inferences). Here we review A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19, by B.Cao et al, published in the New England Journal of Medicine on 18 March 2020. This was one of the first randomised controlled trials of treatments for COVID-19 to be published, and the first in a high-profile medical journal.

Files (148.9 kB)
Name Size
Review_20_03_28_Cao.pdf
md5:c139dbcfe8d74902ab4682026f95e384
148.9 kB Download
1,286
730
views
downloads
All versions This version
Views 1,286972
Downloads 730563
Data volume 108.8 MB83.8 MB
Unique views 1,101861
Unique downloads 648517

Share

Cite as